$STRO News
Last published 1w ago
- 1w agoSTROSutro Biopharma to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
- 3w agoSTROSutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid TumorsGlobeNewswire— STRO-006 is Sutro’s second wholly-owned ADC to enter the clinic in less than one year — — Initial clinical data expected in the second half of 2027 — SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE
- 1mo agoSTROSutro Biopharma Announces Participation at the 17th Annual World ADC ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
- 3mo agoSTROSutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 StudyGlobeNewswire– Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study – – Strong execution
- 5mo agoSTROJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - SUTRO BIOPHARMA INCEarnings Call TranscriptsWelcome, everyone, to Jefferies' 2026 Global Healthcare Conference. My name is Roger Song, Senior Analyst, covers Semicat Biotech. It is my great pleasure to introduce our next company, Sucral Biopharm, and then having a
- 6mo agoSTROSutro Biopharma Reports First Quarter 2026 Financial Results and Business HighlightsGlobeNewswire– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 – – Continued advancement of wholly-owned pipeline,
- 6mo agoSTROSutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026GlobeNewswireSTRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent
- 7mo agoSTROSutro Biopharma Reports Full Year 2025 Financial Results and Business HighlightsGlobeNewswire– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned dual-payload program
- 8mo agoSTROSutro Biopharma to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
- 8mo agoSTROSutro Biopharma Announces Participation at the 16th World ADC London SummitGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
- 9mo agoSTROSutro Biopharma Announces Pricing of $110.0 million Underwritten OfferingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
- 10mo agoSTROSutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
- 10mo agoGTBPADCTSTROCRNX+1Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma PipelinesPR NewswireEquity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has signaled smart money abandoning...
- 10mo agoSTROSutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
- 11mo agoSTROSutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
- 11mo agoSTROSutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid TumorsGlobeNewswire– Initial clinical data expected mid-2026 – SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical stage oncology company pioneering
- 11mo agoSTROSutro Biopharma Announces 1-for-10 Reverse Stock SplitGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug
- 12mo agoSTROSutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D DayGlobeNewswire- Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC - - Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 - - Investor webcast today
- 1y agoSTROSutro Biopharma Reports Third Quarter 2025 Financial Results and Business HighlightsGlobeNewswire– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end – – Company presented new
- 1y agoSTROSutro Biopharma to Host Virtual Research & Development Day on November 12, 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),
- 1y agoSTROSutro Biopharma Announces Participation at the 16th Annual World ADC ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),
- 1y agoSTROSutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key MilestonesGlobeNewswire– Extends cash runway into at least mid-2027 –
- 1y agoONCYIBRXAGENSTRO+1FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market MilestonePR NewswireFederal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with...
- 1y agoSTROSutro Biopharma Reports Second Quarter 2025 Financial Results and Business HighlightsGlobeNewswire– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 – – Expanded breadth of preclinical data across pipeline, including STRO-006 and dual-payload ADCs –
- 1y agoSTROSutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug ConjugatesGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),
- 1y agoSTROSutro Biopharma Appoints Greg Chow as Chief Financial OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),
- 1y agoSTROSutro Biopharma Reports First Quarter 2025 Financial Results and Business HighlightsGlobeNewswire- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as
- 1y agoSTROSutro Biopharma to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),
- 1y agoONCYSTROBCTXBCTXW+2New Cancer Treatments Spark Hope as Traditional Funding Faces UncertaintyPR NewswireEquity Insider News Commentary – Optimism in the field of oncology is on the rise, thanks to the National Institutes of Health's latest annual...
- 1y agoSTROSutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),
- 1y agoSTROSutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),
- 1y agoSTROSutro Biopharma Reports Full Year 2024 Financial Results and Business HighlightsGlobeNewswire– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable
- 1y agoSTROSutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC PipelineGlobeNewswire– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs
- 1y agoSTROSutro Biopharma to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
- 1y agoSTROSutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
- 1y agoSTROSutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scaleGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that they successfully applied Sutro's proprietary cell-free expression
- 1y agoSTROSutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian CancerGlobeNewswire- 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose for randomized portion (Part 2) of ongoing registrational REFRαME-O1 trial - - These data confirm luvelta's
- 1y agoSTROSutro Biopharma Reports Third Quarter 2024 Financial Results and Business HighlightsGlobeNewswire- Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology - - Two new clinical trials, REFRαME-P1, a registration-enabling trial of luvelta for
- 2y agoSTROSutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
- 2y agoSTROSutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AMLGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
- 2y agoSTROSutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research ForumGlobeNewswireProprietary cell-free platform enables the design of next-generation ADCs intended to broaden addressable patient populations STRO-004 (tissue factor ADC) preclinical data has demonstrated greater anti-tumor activity
- 2y agoSTROSutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody-drug
- 2y agoONCYNVSLNTHSTRO+1Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology PlayersPR NewswireUSA News Group – In the oncology world, there's been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years. However,...
- 2y agoSTROSutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024GlobeNewswire- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian cancer and was
- 2y agoSTROSutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024GlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
- 2y agoSTROSutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung CancerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
- 2y agoSTROSutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesGlobeNewswire- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025
- 2y agoSTROSutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
- 2y agoSTROSutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesGlobeNewswire- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient
- 2y agoSTROSutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 TrialGlobeNewswire– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1